Safety of a 3-weekly schedule of carboplatin pegylate liposomal doxorubicin as first line chemotherapy results in patients with ovarian cancer preliminary results of the MITO-2 randomized trial

Pignata S;Scambia G;Savarese A;Breda E;Scollo P;De Vivo R;Rossi E;Gebbia V;Natale D;Del Gaizo F;Naglieri E;Ferro A;Musso P;D'arco A M;Sorio R;Pisano C;Di Maio M;Signoriello G;Annunziata A;Perrone F

2006-01-01